Postoperative wounds

Sorbact® dressings for postoperative wounds

Surgical site infections (SSIs) are a huge health problem worldwide. SSI is a common postoperative complication in vascular, obstetric, gynecologic, gastric, thoracic, and cardiovascular surgery. It prolongs hospitalization and contributes to significant morbidity and mortality.1,2

Read more about Sorbact® in caesarean section

Don't forget the last step

Several actions are being taken to prevent surgical site infections, both preoperative, during and after the operation, e.g. pre-op disinfectants, two pairs of gloves and effective ventilation. However, one important factor that is often missed in the overall strategy is to reduce microbes at the incision site and the preventive and treatment role of using a suitable dressing. This is stated in the recent international guidelines (scroll down).

National Institute for Health and Care Excellence in UK

Sorbact® is recommended by NICE3

NICE medical technologies guidance mtg55 suggests that Leukomed® Sorbact®:

  • Reduces SSI in caesarean section and vascular surgery
  • May reduce antibiotic use
  • May reduce readmissions from wound complications
  • Could save the NHS up to £5.3 million per year for caesarean section and up to £1.2 million per year for vascular surgery
  • Cost savings are expected

Learn more

Leukomed® is a registered trademark of BSN Medical GmbH


Sorbact® for preventing and managing SSI across health care sectors

In these international guidelines Sorbact® is recommended across health care sectors.4 It can be used for infection prevention as well as for treating infected surgical wounds.

See table 9 – Wound dressings for the management of surgical wounds (page 33).

Learn more

Sorbact® reduces the risk of infection in wounds

Sorbact® bacteria and fungi binding dressings prevent and treat wound infections by lowering the bioburden.5,6 Bacteria irreversibly bind and anchor to the unique Sorbact® surface. Safe and effective removal of bacteria reduces the bioburden in wounds which facilitates the healing process. With the Sorbact® mode of action, development of bacterial or fungal resistance is not expected.

Since there are no active agents released into the wound7, Sorbact® dressings can be used right from the start, in all patients, in the short-term or for prolonged treatment of already infected wounds.

Hand holding a smartphone showing Sorbact value calculator

Calculate the potential value of preventing SSI

SSI has become a huge public health problem because it contributes to significant morbidity, mortality and financial consequences. An SSI is estimated to add approximately 3–21 days to a patient’s hospital stay. This results in additional treatment costing between 900€–7300€8, depending on the type of surgery and severity of the infection.2, 8

Start calculator

Estimate the cost of SSIs

Number of procedures per period

Current incidence of SSI

Potential incidence of SSI

Please select a lower value than Current incidence

Average cost of an SSI

The cost of dressings (to protect and prevent infection) is not included in the calculation. It is often a minor part of the total.


total number of SSIs

less SSIs


total cost

cost savings for SSI

Add no of procedures per period

A period is often a year for hospital, region or country.

Current incidence of SSI

The incidence rate (the % of new SSIs within a time period) following a caesarean section varies between 3%-15%1, it’s 10-15% following vascular surgery, rising to 30% in trials specifically monitoring SSI as an outcome.2,3

1.Saeed KBM, Greene RA, et al. 2017. Incidence of surgical site infection following caesarean section: a systematic review and meta-analysis protocol. BMJ Open. 7:e013037. link

2.Matatov T, Reddy KN, et al. 2013. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 57(3):791-795. link

3.Turtiainen J, Saimanen EIT, et al. 2012. Effect of triclosan-coated sutures on the incidence of surgical wound infection after lower limb revascularization surgery: a randomized controlled trial. World J Surg. 36(10):2528-2534. link

Potential incidence of SSI

The potential incidence is the expected incidence after a change has been introduced that affects the current incidence.

Average cost of an SSI

Average cost for treating an SSI is approximately 4400€ at 2017 prices.1,2 The main cost driver is extra length of stay in hospital. Approximate additional costs attributable to SSI vary between 900€-7300€ depending on the type of surgery and the severity of the infection.3

Total cost of SSIs = number of SSIs x average cost of an SSI

1.Jenks PJ, Laurent M, et al. 2014. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect. 86(1)

2.Stanirowski PJ, Davies H, et al. 2019. Cost-effectiveness of a bacterial-binding dressing to prevent surgical site infection following caesarean section. J Wound Care. 28(4)

3.Leaper DJ, Van Goor H, et al. 2004. Surgical site infection – a European perspective of incidence and economic burden. Int Wound J. 1(4)

Evidence on Sorbact® in postoperative wounds

Proven to prevent and treat wound infection in more than 40 clinical studies and in publications including over 7,000 patients, Sorbact® has more than 30 years of successful use in clinical practice. Today Sorbact® is helping patients in over 65 countries around the world and we are continuing this important work by collecting clinical data.

Cohort study

Sorbact®reduces the incidence of SSI in vascular surgery

A comparative study to assess the impact of Sorbact® on the incidence of SSI in vascular surgery. 200 patients undergoing vascular surgery. Rate of SSI day 5-7:10% (Control) vs 1% (Sorbact®) p=<0.01. Rate of SSI day 30:19% (Control) vs 10% (Sorbact®) p=0.11.

Bua N, Smith GE, et al. 2017. Dialkylcarbamoyl Chloride Dressings in the Prevention of Surgical Site Infections after Nonimplant Vascular Surgery. Ann Vasc Surg. 44:387-392.

Published study

Sorbact® prevents wound infections

A randomized controlled study among 543 patients undergoing elective or emergency caesarean section, comparing Sorbact® Surgical Dressing to standard surgical dressing (1.8 % vs. 5.2 %) p=0.04.

Stanirowski PJ, Bizoń M, et al. 2016. Randomized Controlled Trial Evaluating Dialkylcarbamoyl Chloride Impregnated Dressings for the Prevention of Surgical Site Infections in Adult Women Undergoing Cesarean Section. Surg Infect (Larchmt). 17(4):427-435.

Read more about Sorbact® in caesarean section


1.WHO. 2011. Report on the burden of endemic health care-associated infection worldwide. Geneva: World Health
2.European Centre for Disease Prevention and Control. 2013. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm:
3.NICE. 2021. Leukomed Sorbact for preventing surgical site infection. NICE National Institute for Health and Care Excellence.
4.Stryja J, Sandy-Hodgetts K, et al. 2020. Surgical site infection: preventing and managing surgical site infection across health care sectors. J Wound Care. 29(Sup2b):1-72.  link
5.Gentili V, Gianesini S, et al. 2012. Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed Sorbact. Eur J Clin Microbiol Infect Dis. 31(7)
6.Mosti G, Magliaro A, et al. 2015. Comparative study of two antimicrobial dressings in infected leg ulcers: a pilot study. J Wound Care. 24(3):121-122,
7.Data on file. ABIGO Medical.
8.Leaper DJ, Van Goor H, et al. 2004. Surgical site infection – a European perspective of incidence and economic burden. Int Wound J. 1(4):247-273. link

Unsupported browser

This site probably won't work great in Internet Explorer. We generally only support the recent versions of major browsers like Chrome, Firefox, Safari and Edge.